Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Beta-adrenergic blocking drugs are a widely used, well tolerated and effective treatment for
a variety of cardiovascular and noncardiovascular disorders. Over the years, beta-blockers …

Background Beta‐blocker therapy has mortality benefit in patients with hypertension, heart
failure and coronary artery disease, as well as during the perioperative period. These drugs …

The clinical effects of treatment withn β-adrenoceptor (β-AR) agonists and antagonists in
heart failure vary with duration of therapy, as do the effects of β-AR agonists in asthma …

We present a two-part review of the English-language literature pertaining to drug therapy
for systemic high BP in patients with pulmonary diseases. Part I examines the literature …

Because many antihypertensive drugs can affect airway function, the treatment of
hypertension in patients with airway dysfunction is complex. For example, the worsening or …

The coexistence of coronary artery disease (CAD) and chronic obstructive pulmonary
disease (COPD) is frequent because of common etiological factors. Β-Blockers remain …

Disorders of the heart frequently cause pulmonary dysfunction because of the close
structural and functional association of the heart and lungs. The pulmonary vasculature is …

Pharmacological modulation of β-adrenoceptor function is one of the critical issues in the
treatment of patients with concurrent chronic obstructive pulmonary disease (COPD) and …

The aim of the study was to compare the pulmonary effects of four beta-blockers with
different ancillary properties: propranolol (non-beta 1 selective without ISA), oxprenolol (non …